[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Antoine M, Khitrik-Palchuk M, Saif MW: Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. JOP; 2007;8(6):783-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature.
  • CONTEXT: Acinar cell carcinoma of the pancreas is a rare malignancy that may have acinar and endocrine differentiation.
  • Clinical practice guidelines exist for pancreatic ductal adenocarcinoma.
  • However, treatment protocols for acinar cell carcinoma of the pancreas have not been standardized.
  • CASE REPORT: We describe a case of a 44-year-old woman presenting with low grade fever and mid-abdominal tenderness secondary to a pancreatic mass with acinar and endocrine differentiation metastatic to the liver.
  • The patient received multiple lines of conventional and investigational chemotherapy regimens.
  • The patient developed Clostridium difficile colitis and septic shock resulting in death 37 months after the diagnosis of acinar cell carcinoma of the pancreas.
  • CONCLUSION: This is a case of acinar cell carcinoma of the pancreas with an endocrine component, treated with multiple chemotherapeutic agents, in which the patient survived 37 months after diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993731.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 28
  •  go-up   go-down


2. Kebir FZ, Lahmar A, Arfa N, Manai S, El Ouaer MA, Bouraoui S, Gouttalier C, Mezabi-Regaya S: Acinar cell carcinoma of the pancreas in a young patient with chronic pancreatitis. Hepatobiliary Pancreat Dis Int; 2010 Feb;9(1):103-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas in a young patient with chronic pancreatitis.
  • BACKGROUND: Acinar cell carcinoma (ACC) is a rare malignancy of the pancreas arising from acinar cells.
  • Unlike ductal adenocarcinoma, this tumor rarely presents with pancreatitis.
  • METHODS: We present a case of ACC associated with chronic calcifying pancreatitis, and a review of the literature focusing on diagnosis and management.
  • Histopathological examination of the tissue extracted revealed an ACC.
  • Six months post-operatively, the patient developed hepatic metastasis and was treated with gemcitabine as palliative chemotherapy.
  • CONCLUSIONS: The clinical presentation of ACC of the pancreas is not specific and the tumor can be under-diagnosed when associated with chronic pancreatitis.
  • Data regarding course, treatment, and prognosis of this tumor are generally lacking.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis, Chronic / complications

  • Genetic Alliance. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20133240.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Distler M, Rückert F, Dittert DD, Stroszczynski C, Dobrowolski F, Kersting S, Grützmann R: Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy. World J Surg Oncol; 2009;7:22
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy.
  • BACKGROUND: Acinar cell carcinoma (ACC) represents only 1-2% of pancreatic cancers and is a very rare malignancy.
  • At the time of diagnosis only 50% of the tumors appear to be resectable.
  • Reliable data for an effective adjuvant or neoadjuvant treatment are not available.
  • MRI-imaging showed a tumor within the head of the pancreas concomitant with Serum-Lipase and CA19-9.
  • Endosonographic fine needle biopsy confirmed an acinar cell carcinoma.
  • Chemotherapy was well tolerated, and no severe complications were observed.
  • Histopathological examination gave evidence of a diffuse necrotic ACC-tumor, all resection margins were found to be negative.
  • Therefore, neoadjuvant chemotherapy could be an option to reduce a primarily unresectable ACC to a point where curative resection can be achieved.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Carcinoma, Acinar Cell / surgery. Fluorouracil / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Prognosis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):222-5 [10982618.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1061-7 [17957440.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] Pathol Res Pract. 2002;198(12):777-83 [12608654.001]
  • [Cites] Pancreas. 2003 Jul;27(1):e18-22 [12826914.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):67-72 [15361637.001]
  • [Cites] Br Med J. 1970 Jun 20;2(5711):708-9 [5429656.001]
  • [Cites] Cancer. 1974 Apr;33(4):1002-9 [4819206.001]
  • [Cites] J Clin Pathol. 1977 Feb;30(2):103-12 [845259.001]
  • [Cites] Radiology. 1979 Feb;130(2):345-6 [760147.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Gastroenterol Jpn. 1992 Dec;27(6):785-91 [1281798.001]
  • [Cites] Dig Surg. 1999;16(1):76-9 [9949272.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):511-9 [15671372.001]
  • [Cites] Pancreas. 2007 Jul;35(1):42-6 [17575544.001]
  • [Cites] JOP. 2007;8(6):783-9 [17993731.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):938-44 [10987254.001]
  • (PMID = 19239719.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2657786
  •  go-up   go-down


Advertisement
4. Mueller SB, Micke O, Herbst H, Schaefer U, Willich N: Alpha-fetoprotein-positive carcinoma of the pancreas: a case report. Anticancer Res; 2005 May-Jun;25(3A):1671-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein-positive carcinoma of the pancreas: a case report.
  • We report on the case of a 19-year-old male with an alpha-fetoprotein (AFP)-producing acinar cell carcinoma of the pancreas.
  • Because of inoperability, a combined radiochemotherapy was initiated with a hyperfractionated dose of 44.8 Gy.
  • Initially, the tumour showed a good response to irradiation and 5-fluorouracil (5-FU) application, and therapy showed sufficient local control.
  • After combined radio-chemotherapy, AFP levels declined from about 3000 ng/ml (reference area: 0-7 ng/ml) to 18 ng/ml, but increased when widespread metastasis appeared.
  • The patient died 18 months after the initial therapy due to general tumour progression.
  • Originally, AFP was thought to be specific to hepatocellular carcinoma and germ cell tumours.
  • Rare cases of acinar cell carcinomas of the pancreas were found to express AFP.
  • When present, AFP expression is useful for diagnosis and as a marker for monitoring therapeutic response and recurrence of the disease.
  • [MeSH-major] Pancreatic Neoplasms / metabolism. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033080.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


5. Kolb-van Harten P, Rosien U, Klöppel G, Layer P: Pancreatic acinar cell carcinoma with excessive alpha-fetoprotein expression. Pancreatology; 2007;7(4):370-2
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic acinar cell carcinoma with excessive alpha-fetoprotein expression.
  • We report a case of acinar cell carcinoma of the pancreas associated with excessively elevated levels of serum alpha-fetoprotein (>32,000 ng/ml).
  • Abdominal computed tomography scan revealed a large pancreatic mass with infiltration of the splenic artery.
  • Because of inoperability, palliative combination chemotherapy with gemcitabine and mitomycin C was administered.
  • [MeSH-major] Carcinoma, Acinar Cell / metabolism. Pancreatic Neoplasms / metabolism. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Gene Expression Regulation, Neoplastic. Humans. Male. Mitomycin / therapeutic use

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel and IAP
  • (PMID = 17703084.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins; 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


6. Holen KD, Klimstra DS, Hummer A, Gonen M, Conlon K, Brennan M, Saltz LB: Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol; 2002 Dec 15;20(24):4673-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors.
  • PURPOSE: Acinar cell carcinoma is a rare tumor of the exocrine pancreas.
  • Clinical features such as prognostic information, survival, and treatment outcomes are unknown.
  • PATIENTS AND METHODS: Thirty-nine patients with pathologically confirmed acinar neoplasms of the pancreas were identified between August 1981 and January 2001.
  • Demographic data, tumor characteristics, and treatment information were obtained by chart review.
  • On the basis of a univariate analysis, the patients' stage of disease correlated significantly with survival.
  • Patients who could be treated with surgery as first-line therapy had a longer survival time (36 months) compared with those who did not have surgery (14 months).
  • Two of 18 patients who received chemotherapy and three of eight patients who received radiation had a major response.
  • CONCLUSION: The survival curves suggest a more aggressive cancer than pancreatic endocrine neoplasms but one that is less aggressive than ductal adenocarcinoma of the pancreas.
  • There is a high recurrence rate after complete surgical resection, suggesting that micrometastases are present even in localized disease and that adjuvant therapies may be indicated.
  • Chemotherapy and radiation afford disappointing results, however, and novel therapies are needed.
  • [MeSH-major] Carcinoma, Acinar Cell / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12488412.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Morishima K, Hyodo M, Nihei Y, Sata N, Yasuda Y: [A case of acinar cell carcinoma of pancreas with liver metastases treated effectively by S-1]. Gan To Kagaku Ryoho; 2010 Jan;37(1):127-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of acinar cell carcinoma of pancreas with liver metastases treated effectively by S-1].
  • A 65-year-old man underwent a total gastrectomy and distal pancreatectomy for acinar cell carcinoma of the pancreas.
  • He was treated with S-1 chemotherapy over 34 months, and the tumors significantly reduced in size without severe side effects.
  • Acinar cell carcinoma of the pancreas is a rare and highly malignant tumor, and there are few reports regarding treatment with chemotherapy.
  • Herein, we report a case with multiple liver metastases which were controlled by systemic chemotherapy using S-1.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Oxonic Acid / therapeutic use. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Gastrectomy. Hepatectomy. Humans. Male. Pancreatectomy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087046.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


8. Michl J, Scharf B, Schmidt A, Huynh C, Hannan R, von Gizycki H, Friedman FK, Brandt-Rauf P, Fine RL, Pincus MR: PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer; 2006 Oct 1;119(7):1577-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo.
  • PNC-28 is a p53 peptide from its mdm-2-binding domain (residues 17-26), which contains the penetratin sequence enabling cell penetration on its carboxyl terminal end.
  • We have found that this peptide induces necrosis, but not apoptosis, of a variety of human tumor cell lines, including several with homozygous deletion of p53, and a ras-transformed rat acinar pancreatic carcinoma cell line, BMRPA1. Tuc3.
  • On the other hand, PNC-28 has no effect on untransformed cells, such as rat pancreatic acinar cells, BMRPA1, and human breast epithelial cells and no effect on the differentiation of human stem cells.
  • When delivered concurrently with tumor explantation at a remote site, PNC-28 causes a complete blockade of any tumor growth during its 2-week period of administration and 2 weeks posttreatment, followed by weak tumor growth that plateaus at low tumor sizes compared with tumor growth in the presence of a control peptide.
  • [MeSH-major] Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Peptide Fragments / toxicity. Tumor Suppressor Protein p53 / toxicity
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Humans. Mice. Mice, Nude. Rats. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16688716.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA42500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PNC-28; 0 / Peptide Fragments; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


9. Fujii M, Sato H, Ogasawara T, Ando T, Tsujii S, Nagahori J, Komatsu Y, Matsuoka A: [A case of liver metastasis of pancreatic acinar cell carcinoma treated with S-1 and intra-arterial CDDP combination therapy]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1987-90
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of liver metastasis of pancreatic acinar cell carcinoma treated with S-1 and intra-arterial CDDP combination therapy].
  • A 55-year-old man underwent a pylorus-preserving pancreatoduodenectomy in August 2006 because of acinar cell carcinoma of the head of the pancreas.
  • Since abdominal CT revealed multiple liver metastases, we started systemic chemotherapy with gemcitabine (1,400 mg/body, day 1, 8, 15/q4w) in October 2006.
  • At the beginning of this treatment, it seemed to be a stable disease, but CT revealed tumor progression in January 2007.
  • Despite the change to oral chemotherapy with S-1 (100 mg/body, day 1-14/q3w), tumors were markedly enlarged in March 2007.
  • Therefore, we selected combination chemotherapy with oral S-1 and hepatic arterial infusion of CDDP (50 mg/body) as third-line.
  • After 6 months of treatment, abdominal CT revealed marked shrinkage of tumors, accompanied by a decrease in AFP level.
  • Though the patient died of hepatic failure in July 2009 (33 months after recurrence), he spent most of his time at home and worked as usual.
  • We suggest that combination chemotherapy with oral S-1 and intra-arterial CDDP can be effective treatments for pancreatic acinar cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Cisplatin / therapeutic use. Liver Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Pancreatic Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Fatal Outcome. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Recurrence. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948270.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Illyés G, Luczay A, Benyó G, Kálmán A, Borka K, Köves K, Rácz K, Tulassay T, Schaff Z: Cushing's syndrome in a child with pancreatic acinar cell carcinoma. Endocr Pathol; 2007;18(2):95-102
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's syndrome in a child with pancreatic acinar cell carcinoma.
  • A case of pancreatic acinar cell tumor (ACC) is presented in a 10-year-old boy.
  • Biopsy of the mass showed a solid, poorly differentiated ACC of the pancreas.
  • Serum ACTH and cortisol levels dropped progressively and definitively to normal values after chemotherapy, and the Cushing's syndrome subsided.
  • [MeSH-major] Carcinoma, Acinar Cell / complications. Cushing Syndrome / etiology. Pancreatic Neoplasms / complications
  • [MeSH-minor] Adrenocorticotropic Hormone / blood. Child. Fatal Outcome. Humans. Hydrocortisone / blood. Immunohistochemistry. Laparotomy. Male. Microscopy, Electron. Tomography, X-Ray Computed. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pancreatol. 2000 Jun;27(3):249-57 [10952408.001]
  • [Cites] Arch Dis Child. 1988 Dec;63(12):1494-6 [2852926.001]
  • [Cites] Semin Diagn Pathol. 2000 May;17(2):104-8 [10839610.001]
  • [Cites] Pediatr Surg Int. 2001 Nov;17(8):614-20 [11727051.001]
  • [Cites] Neuroscience. 1990;37(1):31-44 [1978740.001]
  • [Cites] J Comput Assist Tomogr. 2004 Mar-Apr;28(2):180-6 [15091120.001]
  • [Cites] Hum Pathol. 1992 Jul;23(7):828-30 [1377164.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;416(3):265-70 [1689089.001]
  • [Cites] J Pediatr Surg. 2002 Jun;37(6):887-92 [12037756.001]
  • [Cites] Acta Radiol. 2003 Jan;44(1):103-6 [12631008.001]
  • [Cites] Radiat Med. 1999 Sep-Oct;17(5):365-8 [10593288.001]
  • [Cites] Med Pediatr Oncol. 2001 Jul;37(1):47-52 [11466723.001]
  • [Cites] J Clin Pathol. 1996 Nov;49(11):952-4 [8944621.001]
  • [Cites] Br Poult Sci. 1998 Mar;39(1):123-7 [9568309.001]
  • [Cites] Histochem Cell Biol. 2003 May;119(5):405-13 [12743826.001]
  • [Cites] Virchows Arch. 1994;424(5):485-90 [8032529.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S83-7 [11762358.001]
  • [Cites] Eur J Endocrinol. 1998 Apr;138(4):436-9 [9578513.001]
  • [Cites] Ultrastruct Pathol. 2000 Jul-Aug;24(4):227-41 [11013963.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):953-62 [11891193.001]
  • [Cites] Pancreas. 2006 Oct;33(3):311-2 [17003655.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] Gut. 1995 Oct;37(4):544-51 [7489943.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1671-4 [16033080.001]
  • [Cites] Gastroenterol Clin Biol. 1997;21(3):231-2 [9161503.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):222-5 [10982618.001]
  • [Cites] Infect Immun. 2002 Nov;70(11):6068-74 [12379683.001]
  • [Cites] JOP. 2004 May;5(3):151-4 [15138338.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1619-27 [11696422.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):938-44 [10987254.001]
  • [Cites] Hepatogastroenterology. 1992 Jun;39(3):282-6 [1380476.001]
  • [Cites] Regul Pept. 2004 Dec 15;123(1-3):209-16 [15518914.001]
  • (PMID = 17917000.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


11. Seki Y, Okusaka T, Ikeda M, Morizane C, Ueno H: Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent. Jpn J Clin Oncol; 2009 Nov;39(11):751-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent.
  • Pancreatic acinar cell carcinoma (ACC) is a comparatively rare tumor and account for approximately 1% of all cases of pancreatic cancer.
  • The clinical features, especially those related to the prognosis and treatment outcomes, have not yet been fully clarified.
  • There are no established treatments for unresectable pancreatic ACC.
  • On the other hand, fluoropyrimidine-based chemotherapy may have some activity against this tumor, because one of the three patients who received S-1 as second-line chemotherapy showed a partial response.
  • Prospective clinical trials are necessary to confirm the effectiveness of fluoropyrimidine for the treatment of pancreatic ACC.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Deoxycytidine / analogs & derivatives. Oxonic Acid / therapeutic use. Pancreatic Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Disease-Free Survival. Drug Combinations. Female. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19666905.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


12. Sorscher SM: Metastatic acinar cell carcinoma of the pancreas responding to gemcitabine, 5-fluorouracil and leucovorin therapy: a case report. Eur J Cancer Care (Engl); 2009 May;18(3):318-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic acinar cell carcinoma of the pancreas responding to gemcitabine, 5-fluorouracil and leucovorin therapy: a case report.
  • Acinar cell carcinoma of the pancreas is rare tumour with a generally poor prognosis.
  • There are very few reports of tumour regression following chemotherapy.
  • In this case report, a patient with metastatic acinar cell carcinoma in the liver developed progressive disease after cisplatin/etoposide and then had progressive disease after weekly paclitaxel chemotherapy.
  • However, his tumour then responded to gemcitibine/5-flourouracil/leucovorin chemotherapy.
  • Herein, previously described chemotherapy regimens used for this rare tumour are reviewed.
  • This case represents the first reported metastatic acinar cell carcinoma responding to this regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Liver Neoplasms / drug therapy. Pancreatic Neoplasms
  • [MeSH-minor] Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Treatment Outcome. Vitamin B Complex / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19445023.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 12001-76-2 / Vitamin B Complex; B76N6SBZ8R / gemcitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Kataoka Y, Nio Y, Yano S, Koike M, Hashimoto K, Itakura M, Itagaki T, Nishi T, Endo S, Higami T: [Pancreatic acinar cell carcinoma successfully treated with combination of oral TS-1 and intra-arterial cisplatin]. Gan To Kagaku Ryoho; 2006 Apr;33(4):525-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic acinar cell carcinoma successfully treated with combination of oral TS-1 and intra-arterial cisplatin].
  • Pancreatic acinar cell carcinomas are rare, and little is reported on their chemotherapy.
  • We report a 49-year old male patient with pancreatic acinar cell carcinoma and multiple liver metastases, which responded to oral TS-1 and hepatic arterial infusion of cisplatin.
  • The patient underwent a partial hepatectomy, MCT abrasions and excision of the pancreatic tumor.
  • Postoperative pathological studies revealed metastases of acinar cell carcinoma to the liver and lymph nodes; the primary lesion was undetermined.
  • Abdominal CT one year after surgery revealed a pancreatic body tumor, which was surgically removed.
  • Pathological studies showed primary pancreatic acinar cell carcinoma, while previous metastases remained under control.
  • To summarize, TS-1 and cisplatin can be effective treatments for pancreatic acinar cell carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Hepatectomy. Humans. Infusions, Intra-Arterial. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Male. Middle Aged. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612167.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Duffy JP, Reber HA: Pancreatic neoplasms. Curr Opin Gastroenterol; 2003 Sep;19(5):458-66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic neoplasms.
  • PURPOSE OF REVIEW: This review describes significant basic science and clinical advances in the field of pancreatic neoplasms.
  • RECENT FINDINGS: Some of the genetic and molecular bases for the aggressive behavior of pancreatic cancer have been uncovered, and new targets for therapy have been identified.
  • Various techniques for diagnosis and staging of this disease-endoscopic ultrasound, laparoscopy-continue to undergo evaluation.
  • The concept that locally invasive pancreatic cancer can be effectively downstaged and later resected has been called into question.
  • Regional chemotherapy has shown promise, especially when combined with immunotherapy.
  • Acinar cell carcinomas are rare pancreatic neoplasms associated with postresection survival longer than ductal adenocarcinoma but shorter than endocrine carcinoma.
  • Neoplasms metastatic to the pancreas can be resected safely and with improved survival compared with nonsurgical therapies.
  • SUMMARY: The treatment of pancreatic neoplasms remains a major challenge for physicians and surgeons.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15703589.001).
  • [ISSN] 0267-1379
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Riechelmann RP, Hoff PM, Moron RA, da Câmera Lopes LH, Buzaid AC: Acinar cell carcinoma of the pancreas. Int J Gastrointest Cancer; 2003;34(2-3):67-72
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas.
  • Acinar cell carcinoma of the pancreas is a rare tumor for which the best chemotherapy regimen has not been clearly established.
  • To our knowledge, this is the first time that paclitaxel has been associated with an objective response in this disease.
  • We present her case in detail and review the available literature regarding this rare type of tumor.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Carcinoma, Acinar Cell / pathology. Paclitaxel / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Disease-Free Survival. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 2001 Apr;22(3):326-9 [11291937.001]
  • [Cites] Semin Oncol. 1979 Sep;6(3):285-97 [228430.001]
  • [Cites] Surg Clin North Am. 2001 Jun;81(3):527-42 [11459269.001]
  • [Cites] Int Surg. 1984 Oct-Dec;69(4):361-4 [6084650.001]
  • [Cites] Dig Surg. 1999;16(1):76-9 [9949272.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):685-98 [8362971.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1137-42 [6318961.001]
  • [Cites] J Pathol. 1985 May;146(1):17-29 [2989468.001]
  • [Cites] N Engl J Med. 2002 Nov 28;347(22):1783-91 [12456855.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):855-62 [12417506.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] Cancer. 1976 Mar;37(3):1508-18 [1260669.001]
  • [Cites] Virchows Arch. 1994;424(5):485-90 [8032529.001]
  • [Cites] Gut. 1990 Aug;31(8):953-5 [2387523.001]
  • [Cites] South Med J. 1977 Mar;70(3):370-2 [847494.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] Pancreas. 2001 Jul;23(1):109-12 [11451140.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Gan To Kagaku Ryoho. 1996 Sep;23(11):1614-6 [8854820.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Jan;16(1):107-11 [11206307.001]
  • [Cites] APMIS. 1995 Jan;103(1):69-78 [7695893.001]
  • (PMID = 15361637.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


16. Haas M, Laubender RP, Stieber P, Holdenrieder S, Bruns CJ, Wilkowski R, Mansmann U, Heinemann V, Boeck S: Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol; 2010 Aug;31(4):351-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
  • The objective of this study was to define prognostic serum biomarkers that could serve as surrogate survival endpoints during second-line treatment for advanced pancreatic cancer.
  • This retrospective single-center study included patients treated with second-line therapy for advanced exocrine pancreatic cancer.
  • A pretreatment value and at least one serial measurement during the first two cycles of second-line chemotherapy for CA 19-9, CEA, CRP, and LDH had to be available in order to evaluate the prognostic role of kinetics on overall survival.
  • A cutoff of a >20% increase from baseline during treatment was defined in order to form groups with suspected different outcomes.
  • Overall, 70 patients treated with second-line therapy for advanced disease were included; 94% had distant metastases at treatment initiation.
  • Median time to progression was 2.7 months and median survival 5.4 months.
  • Univariate analysis found that an increase of >20% during treatment was significantly associated with a worse overall survival for CA 19-9 (HR 2.00, p = 0.018), CEA (HR 2.38, p = 0.004), and CRP (HR 3.06, p < 0.001).
  • Serum biomarker kinetics might serve as useful prognostic tools during second-line chemotherapy in advanced pancreatic cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. C-Reactive Protein / metabolism. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. L-Lactate Dehydrogenase / blood. Palliative Care. Pancreatic Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Biomarkers, Tumor / blood. Bone Neoplasms / blood. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Acinar Cell / blood. Carcinoma, Acinar Cell / drug therapy. Carcinoma, Acinar Cell / pathology. Female. Humans. Kinetics. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / blood. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Peritoneal Neoplasms / blood. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 1996 Dec 30;15(24):2797-812 [8981687.001]
  • [Cites] Onkologie. 2003 Oct;26(5):462-7 [14605463.001]
  • [Cites] Oncology. 2007;73(1-2):41-51 [18334830.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Endoscopy. 1993 Jan;25(1):58-68 [8453928.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Sep;62(4):673-8 [18172650.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5918-22 [19029412.001]
  • [Cites] Eur J Surg Oncol. 2000 Aug;26(5):474-9 [11016469.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:145-9 [10436809.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4787-92 [17947726.001]
  • [Cites] Jpn J Clin Oncol. 2007 Feb;37(2):114-20 [17272317.001]
  • [Cites] Oncology. 2008;75(1-2):120-6 [18784438.001]
  • [Cites] Oncology. 2007;73(3-4):221-7 [18424886.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):9-16 [12577228.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):132-8 [18249033.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] Somatic Cell Genet. 1979 Nov;5(6):957-71 [94699.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):547-50 [11801751.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5513-8 [19858379.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1292-7 [18700899.001]
  • [Cites] J Clin Oncol. 1983 Nov;1(11):710-9 [6668489.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2231-7 [19307500.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Future Oncol. 2008 Feb;4(1):41-50 [18240999.001]
  • [Cites] World J Surg. 2009 Apr;33(4):716-22 [19082654.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Cancer. 2009 Jun 15;115(12):2630-9 [19353729.001]
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):195-9 [15999098.001]
  • [Cites] Jpn J Clin Oncol. 2008 Nov;38(11):755-61 [18845521.001]
  • (PMID = 20480409.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 9007-41-4 / C-Reactive Protein; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


17. Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Büchler MW, Giese NA, Friess H: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene; 2005 Jun 23;24(27):4421-32
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis.
  • Altered expression of apoptosis-regulating genes plays an important role in the aggressive growth behavior and chemoresistance of pancreatic ductal adenocarcinoma.
  • In the present study, the hypoxia-inducible proapoptotic gene, BNIP3, was analysed in terms of expression, effect on patient survival, and chemo-responsiveness in pancreatic cancer cell lines. cDNA microarray, real-time light cycler quantitative polymerase chain reaction, laser-capture microdissection, and immunohistochemistry analyses were used to evaluate BNIP3 expression in normal and diseased pancreatic specimens.
  • The effect of chemotherapeutic agents on pancreatic cancer cells was assessed utilizing 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide assays.
  • BNIP3 mRNA levels were 3.0- and 6.3-fold lower in chronic pancreatitis and pancreatic cancer compared to the normal pancreas, respectively.
  • Microdissection analysis confirmed the reduction of BNIP3 expression in pancreatic cancer cells compared to normal duct cells.
  • By immunohistochemistry, BNIP3 was predominantly expressed in the acinar cells of the normal and diseased pancreas.
  • Interestingly, while BNIP3 was undetectable in the cancer cells of 59% of the cases, 75-100% of PanIN2/3 lesions displayed BNIP3 immunoreactivity.
  • Hypoxia induced BNIP3 expression in four out of eight pancreatic cancer cell lines, while it was absent under normoxic and hypoxic conditions in the remaining four.
  • In conclusion, loss of BNIP3 expression occurs late in pancreatic cancer, contributes to resistance to chemotherapy, and correlates with a worsened prognosis.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Membrane Proteins / deficiency. Membrane Proteins / genetics. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology. Proto-Oncogene Proteins / deficiency. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Cell Line, Tumor. Fluorouracil / pharmacology. Humans. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856026.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BNIP3 protein, human; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Dall'igna P, Cecchetto G, Bisogno G, Conte M, Chiesa PL, D'Angelo P, De Leonardis F, De Salvo G, Favini F, Ferrari A, TREP Group: Pancreatic tumors in children and adolescents: the Italian TREP project experience. Pediatr Blood Cancer; 2010 May;54(5):675-80
MedlinePlus Health Information. consumer health - Rare Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic tumors in children and adolescents: the Italian TREP project experience.
  • INTRODUCTION: Malignant pancreatic tumors are exceedingly rare in pediatric age and their clinical features and treatment usually go unappreciated by most pediatric oncologists and surgeons.
  • METHODS: From January 2000 to July 2009, 21 patients <18 years old with pancreatic tumors were prospectively registered in the Italian cooperative TREP project dedicated to very rare pediatric tumors.
  • RESULTS: Tumor types were 4 pancreatoblastomas, 2 pancreatic carcinomas, 3 neoplasms of the endocrine pancreas, and 12 solid pseudopapillary tumors.
  • Three of the four patients with pancreatoblastoma had advanced disease at diagnosis and were given chemotherapy; at the time of this report, three patients were alive in first remission, while one died due to treatment toxicity.
  • Both the cases of pancreatic carcinoma had the acinar cell subtype and successfully underwent pancreaticoduodenectomy with complete tumor resection, remaining without evidence of disease at the time of this analysis.
  • The histological diagnoses of the three endocrine tumors were a malignant islet cell tumor, a gastrinoma, and a well-differentiated tumor.
  • All 12 patients with solid pseudopapillary tumors underwent complete tumor resection and were given no adjuvant treatment; 11 were alive in first remission, while one experienced a local and distant relapse 5 years after diagnosis.
  • CONCLUSIONS: Surgery remains the keystone of treatment for pancreatic tumors in pediatric age as in adults.
  • The TREP project shows that prospective cooperative studies are feasible even for such very rare tumors as these and may serve as a model for developing international cooperative schemes.
  • [MeSH-major] Pancreatic Neoplasms / epidemiology. Rare Diseases / epidemiology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Italy / epidemiology. Male. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2010 May;54(5):659-60 [20063425.001]
  • (PMID = 19998473.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Cavallini A, Falconi M, Bortesi L, Crippa S, Barugola G, Butturini G: Pancreatoblastoma in adults: a review of the literature. Pancreatology; 2009;9(1-2):73-80
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pancreatoblastoma is a very uncommon neoplasm in adults and its management represents a great challenge with regards to different treatment options.
  • METHODS: Adult patients with histologically proven pancreatoblastoma were identified from our prospective database of pancreatic resections.
  • After a search on the Medline database, a review of all cases was performed as well, focusing on clinical, radiological and hystopathological features and treatment options.
  • RESULTS: At our Institution, 2 adult males, 26 and 69 years old, underwent successful pancreatic resection for pancreatoblastoma.
  • The diagnosis of pancreatoblastoma mainly depends on the pathological findings characterized by squamoid corpuscles at histopathology.
  • In general, despite aggressive treatment, pancreatoblastoma in adults is associated with poorer outcome than in children, with a median survival time of 18.5 months.
  • The differential diagnosis includes nonfunctional pancreatic endocrine tumor, acinar cell carcinoma, solid pseudopapillary tumor and adenocarcinoma.
  • Surgical resection is the only treatment associated with long-term survival.
  • Chemotherapy may play a role as palliative treatment in advanced disease.
  • [MeSH-major] Carcinoma, Neuroendocrine. Pancreatic Neoplasms
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. Diagnosis, Differential. Humans. Male. Pancreaticoduodenectomy

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel and IAP.
  • (PMID = 19077457.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 36
  •  go-up   go-down


20. Kitagami H, Kondo S, Hirano S, Kawakami H, Egawa S, Tanaka M: Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas; 2007 Jul;35(1):42-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society.
  • OBJECTIVES: Acinar cell carcinoma (ACC) of the pancreas is a rare tumor, and many aspects remain unclear because no large-scale clinical studies have been conducted.
  • METHODS: The present study investigated the clinical characteristics, treatment, and therapeutic outcomes of 115 patients registered in the Pancreatic Cancer Registry of the Japan Pancreas Society, and therapeutic plans were reviewed.
  • CONCLUSIONS: Confirming the diagnosis of ACC preoperatively is difficult, but this diagnosis should be kept in mind while planning surgery for ordinary pancreatic cancer.
  • Once the diagnosis has been confirmed, a possibility of surgical resection should be pursued to achieve better prognosis.
  • If ACC is unresectable or recurrent, chemotherapy is likely to prove useful.
  • Multidisciplinary therapy centering on the role of surgery will need to be established.
  • [MeSH-major] Carcinoma, Acinar Cell / mortality. Pancreatic Neoplasms / mortality. Registries / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Japan / epidemiology. Male. Middle Aged. Neoplasm Staging / statistics & numerical data. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575544.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


21. Mori S, Kondoh S, Ryozawa S, Urayama N, Satake M, Kitoh H, Yamashita H, Nakashima T, Gondo T, Okita K: [A case of AFP producing pancreatic acinar cell carcinoma diagnosed by EUS FNA and treated by intraarterial injection chemotherapy]. Nihon Shokakibyo Gakkai Zasshi; 2004 Feb;101(2):177-82
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of AFP producing pancreatic acinar cell carcinoma diagnosed by EUS FNA and treated by intraarterial injection chemotherapy].
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Carcinoma, Acinar Cell / ultrasonography. Pancreas / pathology. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / ultrasonography. alpha-Fetoproteins / biosynthesis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Cisplatin / administration & dosage. Drug Administration Schedule. Endosonography. Fluorouracil / administration & dosage. Humans. Injections, Intra-Arterial. Male

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15011443.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  • [Number-of-references] 8
  •  go-up   go-down


22. Lee JL, Kim TW, Chang HM, Lee SK, Kim MH, Kang YK, Kim JS, Kim JH: Locally advanced acinar cell carcinoma of the pancreas successfully treated by capecitabine and concurrent radiotherapy: report of two cases. Pancreas; 2003 Jul;27(1):e18-22
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced acinar cell carcinoma of the pancreas successfully treated by capecitabine and concurrent radiotherapy: report of two cases.
  • [MeSH-major] Carcinoma, Acinar Cell / drug therapy. Carcinoma, Acinar Cell / radiotherapy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12826914.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Chen CP, Chao Y, Li CP, Lee RC, Tsay SH, Chi KH, Yen SH, Chang FY, Lee SD: Concurrent chemoradiation is effective in the treatment of alpha-fetoprotein-producing acinar cell carcinoma of the pancreas: report of a case. Pancreas; 2001 Apr;22(3):326-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiation is effective in the treatment of alpha-fetoprotein-producing acinar cell carcinoma of the pancreas: report of a case.
  • [MeSH-major] Carcinoma, Acinar Cell / drug therapy. Carcinoma, Acinar Cell / radiotherapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy. alpha-Fetoproteins / biosynthesis
  • [MeSH-minor] Aged. Biopsy. Carcinoma, Hepatocellular. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Palliative Care. Pancreas / pathology. Tomography, X-Ray Computed. Ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11291937.001).
  • [ISSN] 0885-3177
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


24. Kobayashi S, Ishikawa O, Ohigashi H, Yamada T, Sasaki Y, Imaoka S, Uehara H, Nakaizumi A, Takenaka A, Kasugai T: Acinar cell carcinoma of the pancreas successfully treated by en bloc resection and intraperitoneal chemotherapy for peritoneal relapse: a case report of a 15-year survivor. Pancreas; 2001 Jul;23(1):109-12
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas successfully treated by en bloc resection and intraperitoneal chemotherapy for peritoneal relapse: a case report of a 15-year survivor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Acinar Cell / surgery. Cisplatin / therapeutic use. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Adult. Anastomosis, Surgical. Ascites / etiology. Combined Modality Therapy. Female. Hemoperitoneum / etiology. Hepatic Artery / surgery. Humans. Infusions, Parenteral. Survivors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11451140.001).
  • [ISSN] 0885-3177
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement